News and events

Get a 20% discount on all HMGBiotech products—whether ordering online or offline.

A recent research has highlighted how HMGB1 (High Mobility Group Box 1) protein in its reduced form plays a crucial role in enhancing cancer cell migration and invasiveness through its interaction with the chemokine CXCL12.

The role of High Mobility Group Box Protein 1 (HMGB1) is increasingly emerging in diabetes-associated complications, particularly diabetic encephalopathy (DE) and diabetic kidney disease (DKD).

High-Mobility Group Box-1 protein (HMGB1) plays a core role in the link between ulcerative colitis (UC) and colorectal cancer (CRC), particularly in colitic carcinoma.

Targeting HMGB1 could represent a novel therapeutic approach for mental health disorders related to stroke and sepsis.

World Mental Health Day, occurring on the 10th of October, recalls to us the importance of researches linking inflammation and mental health disorders, in particular major depressive disorder (MDD).

LPS-free HMGB1 proteins allow for safe and accurate in vitro and in vivo researches, in order to go deeper in heart-related diseases.

A recent research, published two weekes ago, shows that nuclear HMGB1 is essential for the anti-tumor activity of CD8 T cells, particularly in enhancing interferon gamma (IFN-γ) production, a key cytokine in tumor elimination.

Emerging research highlights the relevant role of High-Mobility Group Box 1 (HMGB1) in muscular diseases, offering new insights that could inform future therapeutic strategies for SMA.